Neurocrine Biosciences
NBIX
405 hedge funds and large institutions have $8.6B invested in Neurocrine Biosciences in 2020 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 145 increasing their positions, 151 reducing their positions, and 73 closing their positions.
0% less capital invested
Capital invested by funds: $8.63B → $8.6B (-$34.1M)
0.45% less ownership
Funds ownership: 96.28% → 95.84% (-0.45%)
4% less repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 151
3% less funds holding
Funds holding: 418 → 405 (-13)
12% less first-time investments, than exits
New positions opened: 64 | Existing positions closed: 73
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
66% less call options, than puts
Call options by funds: $39.8M | Put options by funds: $116M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$252M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$80.7M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$38.6M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$35.4M |
| 5 |
PA
Perceptive Advisors
New York
|
+$33.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$83.3M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$69.4M |
| 3 |
HM
HealthCor Management
New York
|
-$67.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$62.8M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$61.8M |
NBIX Hedge Fund Activity: Q4 2020 in Review
405 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2020, worth a combined $8.6B — down 0.39% from $8.63B a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of NBIX and 64 opened new positions — a net loss of 9 holders — while 151 trimmed existing stakes and 145 added.
The largest buyer was Janus Henderson Group, adding an estimated $252M. The largest seller was Capital International Investors, cutting an estimated $83.3M.
- 405 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2020, down from 418 in Q3 2020.
- Funds reported $8.6B of Neurocrine Biosciences stock for Q4 2020, down 0.39% quarter-over-quarter.
- 64 funds opened new Neurocrine Biosciences positions in Q4 2020 and 73 closed out, a net change of -9 holders.
- The largest Neurocrine Biosciences buyer in Q4 2020 was Janus Henderson Group, an estimated $252M added.
- The largest Neurocrine Biosciences seller in Q4 2020 was Capital International Investors, an estimated $83.3M sold.
Based on aggregated 13F filings for Q4 2020.